Thymalin
Investigational thymus-derived peptide preparation (immune bioregulator) · Pre-filled pen
Thymalin is a thymus-derived peptide preparation studied for supporting T-cell maturation and balanced immune signalling, functions that tend to decline with age (immunosenescence). Small clinical studies, largely from one research tradition, have reported effects on immune markers in older or stressed individuals. Independent large-trial confirmation is lacking, so its ageing-related use remains investigational.
Studied use areas
- T-cell maturation and adaptive-immune support (research interest)
- Immune-balance and cytokine-regulation markers
- Age-related immune decline / immunosenescence (investigational)
- Resilience under chronic stress load (exploratory)
Safety & status
- Investigational peptide without robust modern controlled-trial safety data; physician supervision required
- Not approved as a medicine by EMA or MHRA
- Not a substitute for vaccination or evidence-based treatment of infection or immune disease
⚕ Clinical note: This is educational information only and not medical advice. Thymalin is investigational; any use should be individualised and determined by a treating physician under appropriate supervision.
Evidence: Grade C — investigational; decades of small, mostly single-tradition human studies, but not an approved medicine in the EU/UK. · References: Peer-reviewed thymic-peptide and bioregulator literature; Immunosenescence and ageing-immunology reviews; EMA/MHRA guidance on unlicensed investigational substances
